z-logo
open-access-imgOpen Access
Molecular modelling of novel ADCY3 variant predicts a molecular target for tackling obesity
Author(s) -
Meropi Toumba,
Pavlos Fanis,
Dimitriοs Vlachakis,
Vassos Neocleous,
Leonidas A. Phylactou,
Nicos Skordis,
Christos S. Mantzoros,
Maria Pantelidou
Publication year - 2021
Publication title -
international journal of molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.048
H-Index - 90
eISSN - 1791-244X
pISSN - 1107-3756
DOI - 10.3892/ijmm.2021.5065
Subject(s) - transmembrane protein , biology , transmembrane domain , genetics , gene , function (biology) , molecular medicine , computational biology , bioinformatics , cell cycle , receptor
Severe early‑onset obesity is mainly attributed to single gene variations of the hypothalamic leptin‑melanocortin system, which is critical for controlling the balance between appetite and energy expenditure. Adenylate cyclase 3 (ADCY3), a transmembrane enzyme localized in primary neuronal cilia, is a key genetic candidate, which appears to have an essential role in regulating body weight. The present study aimed to identify ADCY3 genetic variants in severely obese young patients of Greek‑Cypriot origin by genomic sequencing. Apart from previously reported variants, the novel and probably pathogenic variant c.349T>A, causing a p.Leu117Met substitution within one of the two pseudo‑symmetric halves of the transmembrane part of the protein, was reported. Molecular modelling analysis used to delineate bonding interactions within the mutated protein structure strongly suggested a change in interactive forces and energy levels affecting the pseudo‑twofold symmetry of the transmembrane domain of the protein and probably its catalytic function. These results support the involvement of ADCY3 in the pathology of the disease and point towards the requirement of defining protein function and evaluating the clinical significance of the detected variants.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here